左西孟旦治疗急性失代偿性心力衰竭疗效分析

Efficacy of Levosimendan in Treatment of Patients with Acute Decompensated Heart Failure

目的评价左西孟旦治疗急性失代偿性收缩功能不全心力衰竭患者的临床疗效。方法将60例急性失代偿性收缩功能不全心力衰竭患者随机分为2组,Ⅰ组为左西孟旦+常规药物治疗组,Ⅱ组为常规药物治疗组,比较2组患者治疗后临床疗效。结果Ⅰ组治疗有效率为93%,Ⅱ组治疗有效率为73%,2组间比较,差异有统计学意义(P<0.05);Ⅰ组治疗后左室射血分数(LVEF)、静息时心室率、心功能改善(NYHA分级)均较Ⅱ组更明显,差异有统计学意义(P<0.05);Ⅰ组住院治疗时间(7.90±2.14)d,明显短于Ⅱ组(11.40±3.81)d,差异有统计学意义(P<0.05);N末端B型钠尿肽(NT-pro BNP)、左室舒张末期内径(LVEDD),2组间比较,差异无统计学意义。2组患者均无明显不良反应。结论左西孟旦联合常规药物治疗急性失代偿性收缩功能不全心力衰竭,治疗药量范围内安全有效,可明显提高心力衰竭患者的临床疗效,减少平均住院时间。

Objective To evaluate the clinical efficacy of levosimendan in acute decompensated heart failure patients with systolic dysfunction. Methods Sixty patients with acute decompensated systolic dysfunction heart failure were randomly divided into two groups： Group I（ levosimendan and conventional medical treatment） and Group II（ conventional medical treatment）. We compared the clinical efficacy and adverse reactions after treatment of the two groups. Results Treatment effective rate was 93% in group I and 93% in group II. Comparison between the two groups was statistically difference（ P〈0. 05）. Group I improved more significantly than group II in LVEF,resting ventricular rate and NYHA heart function improvement（ P〈0. 05）. hospital treatment time in group I was significantly shorter than group II（ 7. 90 ± 2. 14 d VS11. 40 ±3. 81 d,P〈0. 05）. NT-pro BNP,LVEDD had no statistical difference between the two groups. All the patients were no significant adverse reactions in the two groups. Conclusion Levosimendan combined with conventional medical treatment of acute decompensated heart failure with systolic dysfunction with dose range is safe and effective,can significantly improve the clinical curative effect of patients with heart failure,and significantly reduces the average days of hospitalization.